Main Menu

Steven Rosenberg, M.D., Ph.D., has pioneered the development of effective immunotherapies for patients with advanced cancer. His studies of cell transfer immunotherapy using tumor infiltrating lymphocytes (TIL) have resulted in durable complete remissions in patients with advanced solid cancers. He has also pioneered the development of gene therapy and was the first to successfully insert foreign genes into humans. His recent studies of the adoptive transfer of genetically modified lymphocytes using chimeric antigen receptors (CAR) or conventional T-cell receptors (TCR) have resulted in the regression of metastatic cancer in patients with lymphomas and solid cancers. His current research is aimed at defining the host immune response of patients to their cancers. These studies emphasize the ability of human lymphocytes to recognize unique cancer antigens and the identification of anti-tumor T-cell receptors that can be exploited to develop new cell transfer immunotherapies. As Chief, Dr. Rosenberg also oversees the Branch’s extensive clinical program aimed at translating scientific advances into effective immunotherapies for patients with advanced cancers arising from the breast, gastrointestinal tract, and pancreas. Dr. Rosenberg was inducted as an NAI Fellow in 2025.